{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T12:26:26Z","timestamp":1774268786758,"version":"3.50.1"},"reference-count":48,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2026,2,17]]},"DOI":"10.1080\/00325481.2026.2639107","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:24:23Z","timestamp":1772727863000},"page":"146-153","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of CAR-T cell therapy in outpatient settings: a critical review of current literature regarding health outcomes, benefits, challenges, and future directions"],"prefix":"10.1080","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1451-0581","authenticated-orcid":false,"given":"Meghana","family":"Reddy","sequence":"first","affiliation":[{"name":"Mysore Medical College and Research Institute","place":["Mysore, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9139-3652","authenticated-orcid":false,"given":"Rahulkumar J.","family":"Amrutiya","sequence":"additional","affiliation":[{"name":"One Brooklyn Health\/Interfaith Medical Center","place":["Brooklyn, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0939-6504","authenticated-orcid":false,"given":"Kaung Htet Hla","family":"Win","sequence":"additional","affiliation":[{"name":"One Brooklyn Health\/Interfaith Medical Center","place":["Brooklyn, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"National Cancer Institute. CAR T cells: engineering immune cells to treat cancer [internet]. Bethesda (MD): NCI; 2013 Dec 6 [cited 2026 Feb 22]. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081599"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03479-y"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.06.004"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010046"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02104"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0690-8"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.017"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.093"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2021.09.004"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020382"},{"key":"e_1_3_5_20_1","unstructured":"U.S. Food and Drug Administration. Risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor (CAR) T cell immunotherapies modified to minimize burden on healthcare delivery system [internet]. Silver Spring (MD): FDA; 2024 Jun 26 [cited 2026 Feb 22]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor-car-t-cell"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00062"},{"key":"e_1_3_5_24_1","unstructured":"U.S. Food and Drug Administration. FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor (CAR) T cell immunotherapies [internet]. Silver Spring (MD): FDA; 2025 Jun 26 [cited 2026 Feb 22]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-eliminates-risk-evaluation-and-mitigation-strategies-rems-autologous-chimeric-antigen-receptor"},{"key":"e_1_3_5_25_1","unstructured":"Foundation for the Accreditation of Cellular Therapy. What FACT accreditation means to patients [internet]. Milwaukee (WI): FACT; [cited 2026 Feb 22]. Available from: https:\/\/www.factglobal.org\/accreditation-process\/what-fact-accreditation-means-to-patients\/"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013239"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002303"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000337577"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020578"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00077-2"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"e_1_3_5_34_1","unstructured":"Canadian Agency for Drugs and Technologies in Health. Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-Cell engager or CAR T-Cell therapy: rapid review [internet]. Ottawa (ON): CADTH; 2024 [cited 2026 Feb 22]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK604827\/"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-174728"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.001"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.256"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e23167"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-025-00614-x"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.342"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.280"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.06.021"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.02.019"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.357"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0734-z"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.12.002"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5945"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-804"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2026.2639107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:48:10Z","timestamp":1774266490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2026.2639107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,17]]}},"alternative-id":["10.1080\/00325481.2026.2639107"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2026.2639107","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}